On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- MHLW Study Group Postpones Decision on Relief System for Victims of Health Damages Due to Anticancer Drugs
November 21, 2011
- After Delay, CSIMC Recommends Listing of Ilaris for Treatment of CAPS
November 21, 2011
- US FDA Revokes Avastin’s Approval for Metastatic Breast Cancer
November 21, 2011
- Former Chuikyo Chairman Prof. Endo Concerned about Increasing Drug Expenditure
November 21, 2011
- CSIMC Subcommittee Approves Special Price Reductions for Combination Drugs
November 18, 2011
- CSIMC Excludes DPC Flat-Sum Reimbursement, Recommends Approval for Reimbursement by Piecework for 5 APIs
November 18, 2011
- Korosho Approves 3 Switch OTC Products Containing Pemirolast
November 18, 2011
- Similar Products to Be Re-Priced by Product Following Market Expansion: CSIMC Expert Subcommittee
November 17, 2011
- Industry Renews Call for Perpetual Introduction of Premium for New Drug Development: CSIMC Expert Subcommittee
November 17, 2011
- Re-pricing of Essential Drugs Discussed at CSIMC
November 17, 2011
- CSIMC Recommends Listing of 9 Products Including Imusera; Recommendation Put on Hold for Ilaris
November 17, 2011
- Plaintiffs to Appeal Against “Unprecedented Unjust Ruling”: Iressa Appeal Trial
November 17, 2011
- Subcommittee to Study “Notification System” for Access to Unapproved Drugs
November 17, 2011
- PM Noda Says “Japan Will Not Lose” Public Health Insurance System in TPP
November 16, 2011
- Health Minister Komiyama Says “Government Position Recognized” in Iressa Case
November 16, 2011
- DPJ’s Medical and Nursing Care WT Discuss Promotion of Generic Drugs
November 16, 2011
- High Court Turns Down Iressa Compensation Appeal
November 16, 2011
- 7-Drug Rule Should Be Relaxed or Eliminated to Promote GE Name Prescribing: Dr Adachi of CSIMC
November 16, 2011
- Mr Sawai of JGA Opposes Reduction in NHI Prices of First Generics
November 16, 2011
- PAFSC Committee Recommends Classification of Isoconazole as Class 1 OTC Drug
November 15, 2011
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…